Celldex Therapeutics Q1 EPS $(0.56) Beats $(0.69) Estimate, Sales $156.00K Miss $920.00K Estimate
Author: Benzinga Newsdesk | May 06, 2024 04:04pm
Celldex Therapeutics (NASDAQ:
CLDX) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.69) by 18.84 percent. This is a 9.68 percent increase over losses of $(0.62) per share from the same period last year. The company reported quarterly sales of $156.00 thousand which missed the analyst consensus estimate of $920.00 thousand by 83.04 percent. This is a 83.87 percent decrease over sales of $967.00 thousand the same period last year.
Posted In: CLDX